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Protective Immunity EHcited by Recombinant Bacille 
Calmette-Guerin (BCG) Expressing Outer Surface 
Protein A (OspA) Lipoprotein: A Candidate Lyme 
Disease Vaccine 
By C. Kendall Stover,* Geetha P. Bansal,* Mark S. Hanson,* 
Jeanne E. Burlein,* Susan R. Palaszynski; James F. Young,* 
Scott Koenig,* Douglas B. Young, g Ariadna Sadziene,~ 
and Alan G. Barbour~ 
From *Medlmmune, Inc, Gaithersburg, Maryland 20878; the *Departments of Microbiology 
and Medicine, University of Texas Health Science Center, San Antonio, Texas 78284; and the 
SMedical Research Center Tuberculosis and Related Infections Unit, Hammersmith Hospital, 
London W12 OHS, United Kingdom 
Stlmmary 
The ~rrent vacdne against uberculosis, Mycobacterium boris strain baciUe Calmette-Guerin (BCG), 
offers potential advantages a  a live, innately immunogenic vaccine vehicle for the expression 
and delivery of protective recombinant antigens (Stover, C. K., V. F. de la Cruz, T. R. Fuerst, 
J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull 
et al. 1991. Nature[Lond]. 351:456; Jacobs, W. R., Jr., S. B. Snapper, L. Lugosi and B. R. Bloom. 
1990. Curt. Top Microbiol. Iramunol. 155:153; Jacobs, W. R., M. Tuckman, and B. R. Bloom. 
1987. Nature [Long]. 327:532); but as an attenuated intracdlular bacterium residing in macrophages, 
BCG would seem to be best suited for eliciting cellular esponses and not humoral responses. 
Since bacterial lipoproteins are often among the most immunogenic of bacterial antigens, we 
tested whether BCG expression of a target antigen as a membrane-associated lipoprotein could 
enhance the potential for a recombinant BCG vaccine to elicit high-titered protective antibody 
responses to target antigens. Immunization of mice with recombinant BCG vaccines expressing 
the outer surface protein A (OspA) antigen of Borrel/a burgdorferi as a membrane-assodated lipoprotein 
resuhed in protective antibody responses that were 100-1,000-fold higher than responses elicited 
by immunization with recombinant BCG expressing OspA cytoplasmicaUy or as a secreted fusion 
protein. Furthermore, these improved antibody responses were observed in heterogeneous mouse 
strains that vary in their immune responsiveness to OspA and sensitivity to BCG growth. Thus, 
expression of protective antigens as chimeric membrane-associated lipoproteins on recombinant 
BCG may resuh in the generation of new candidate vaccines against Lyme borreliosis and other 
human or veterinary diseases where humoral immunity is the protective response. 
(BCG) 1 attenuated "~acille Calmette-Guerin an bovine 
.13 tubercle bacillus used as a vaccine for tuberculosis, offers 
unique advantages for development asa multivalent vaccine 
vehicle for other human pathogens (1-5). In initial studies 
recombinant BCG was shown to elicit both humoral and cel- 
lular responses to heterologous target antigens such as B-galac- 
tosidase, expressed cytoplasmicaUy as hsp60-lacZ gene fusions 
(1). Subsequent s udies in this laboratory have further demon- 
strated cytoplasmic expression of numerous antigens in rBCG, 
but expression levels have proven to be highly variable from 
antigen to antigen, and humoral responses to some cytoplas- 
micaUy expressed antigens, including some antigens expressed 
1 Abbreviations u ed in this paper: BCG, bacille Calmette-Guerin; OspA, 
outer surface protein A; RBS, ribosomal binding site; T, Tween; TX, 
Triton X. 
at high levels (e.g., HIV reverse transcriptase), have been 
difficult o achieve. Furthermore, humoral responses to most 
target antigens expressed in the cytoplasm of rBCG show 
substantial heterogeneity among different inbred mouse strains, 
and even within individuals of a single strain (our unpub- 
lished data). Therefore, approaches to increase the relative im- 
munogenicity of target antigens expressed atlower levels in 
rBCG were considered in an effort to enhance humoral re- 
sponses elicited by rBCG. Since abundant bacterial surface 
proteins are often highly immunogenic, other investigators 
developing Salmonella nd Escherichia coli vaccine vehicles have 
targeted small antigens or epitopes to the bacterial surface 
by expression as fusion proteins with flagella, fimbriae, or 
major outer membrane protein A (OmpA) and • phage 
receptor (LamB) (6-10). As comparable immunogenic pro- 
197 J. Exp. Med. 9 The Rockefeller University Press 9 0022-1007/93/07/0197/13 $2.00 
Volume 178 July 1993 197-209 
tein surface structures have not yet been characterized in
mycobacteria, we have chosen to use signal peptides derived 
from lipoproteins (11) to direct export and membrane- 
associated surface xpression of target antigens in BCG. In 
addition to the potential for improved antigen presentation 
by surface xpression on rBCG, lipid acylation can dramati- 
cally increase the ability of synthetic peptides (12, 13) to elicit 
immune responses. Moreover, lipoproteins of bacterial patho- 
gens are highly immunogenic n vivo and some bacterial li- 
poproteins have been implicated as protective antigens (14-22). 
Possibly the most notable of promising protective bacterial 
lipoprotein antigens is the outer surface protein A (OspA) 
antigen of Borrelia burgdorferi, the causative agent of Lyme 
disease (23-25). A number of studies have implicated OspA 
as a protective antigen and OspA-specific antibodies as pro- 
tective against Lyme borreliosis in the mouse model (26-29). 
Passive transfer of monoclonal and polyclonal sera specific for 
OspA was shown to protect mice against challenge with 
tg burgdoq'eri (26, 27). Removal of antibodies specific for OspA 
greatly diminished the protective component in polyclonal 
sera generated by immunization with whole killed Borrelia 
(28). Studies using non-lipid acylated OspA-glutathione 
S-transferase (OspA-GST) fusion protein in active immuni- 
zations have also demonstrated promising protection in the 
mouse model for Lyme borreliosis; however, protection re- 
quired repeated immunizations with large doses of OspA- 
GST and formulation with CFA, which is unsuitable for 
human use (27-29). As a lipoprotein, OspA is insoluble and 
not expressed well in E. coli; accordingly, OspA can be un- 
wieldy for immunogenicity studies in the laboratory or 
large-scale production as a subunit vaccine (30). Recently, 
however, it was demonstrated that purified OspA lipopro- 
tein (L-OspA) is profoundly more immunogenic than non- 
lipid acylated OspA (NL-OspA), even in the absence of adju- 
vant (31). Since OspA is a bacterial lipoprotein amenable to 
membrane translocation, we used the ospA gene to test the 
function and utility of the rBCG lipoprotein expression vectors 
(LPE vectors) using mycobacterial lipoprotein signal peptides 
that can enable the expression and export of heterologous 
chimeric lipoproteins to the membrane of rBCG. 
In this study we report a comparison of immune responses 
elicited by immunization with rBCG expressing the OspA 
antigen cytoplasmically, asa secreted fusion protein or as a 
membrane-associated lipoprotein. Immunization with rBCG 
expressing OspA as a chimeric lipoprotein, but not as a cyto- 
plasmic or secreted protein, resulted in high-titered antibody 
responses to OspA in all mouse strains tested, including out- 
bred mice. These OspA-specific antibodies inhibited growth 
of ~R burgdorferi in vitro and in vivo, and were protective in 
a mouse model for Lyme borreliosis. This study is a first test 
for a strategy to driver protective membrane-associated li- 
poproteins on live recombinant BCG vaccines, and has resulted 
in the development ofa candidate vaccine against Lyme disease. 
Materials and Methods 
Construction fBCG/E. coli Shuttle Expression Vectors for Expres- 
sion of Ost~l. All expression vectors described in this study are 
derivatives of plasmid pMV206 described by Stover et al. (1) and 
include DNA cassettes ncoding kanamycin resistance, an E. coli 
origin of replication, a mycobacterial plasmid replicon derived from 
Mycobacteriumfortuitum plasmid pAL5000, and a synthetic multiple 
cloning site (MCS). Plasmid pMV251 is a derivative of pMV261 
(1) with overlapping NcoI and BamHI restriction sites at the hsp60 
start codon. A DNA segment spanning the M. tuberculosis (strain 
H37Rv) 19-kD antigen gene promoter, ribosomal binding site 
(RBS), secretion signal, and the first six codons of the mature 
processed protein was amplified by PCR and cloned between the 
XbaI and BamHI sites of pMV206 to construct plasmid p19PS. 
A DNA segment including RBS and the structural gene of the 
BCG ot antigen was amplified by PCR without he ct antigen stop 
codon and cloned between the XbaI and BamHI sites in the MCS 
of plasmid pRB26 (a derivative of pMV206 containing the BCG 
hsp60 promoter) to yield plasmid pAB26. An ospA gene segment 
encoding the ospA gene without he 5' region encoding the signal 
peptide (ospAA1-57) was amplified by PCR using oligonucleotides 
based on published sequence data for/g burgdo~feri st ain B31 (35210; 
American Type Culture Collection (Rockville, MD) OspA (25). 
These primers included a unique BamHI (5' OsloA primer) or SalI 
site (3' ospA primer) at their 5' ends to facilitate directional c oning. 
The resulting OspA PCR gene segment was digested with BamHI 
and SalI to generate cohesive ends at the 5' and 3' ends, respectively, 
and cloned in-frame between the BamHI and SalI sites of plasmids 
pMV261, pAB26, and p19PS to yield plasmids pMV261::ospA, 
pAB26::ospA, and p19PS::ospA.  complete ospA gene (including 
the signal region) was similarly constructed with 5' NcoI site at 
the start codon and cloned between the NcoI and SalI sites of plasmid 
pMV251 to yield pMV251::ospA. 
Culture and Transformation of BCG. All liquid culture of BCG 
substrain Pasteur 1173 A2 was accomplished at 37~ in stationary 
tissue culture flasks (25 cm 2 with 5-10 ml or 75 cm 2 with 15-25 
ml) or roller bottles (490 cm 2 with 100-200 ml or 850 cm 2 with 
200-500 ml) with Dubos media (Difco Laboratories, Detroit, MI) 
supplemented with a 10% volume of albumin dextrose (AD) en- 
richment consisting of 5% BSA fraction V (Sigma Chemical Co., 
St. Louis, MO), 2% dextrose, and 0.85% sodium chloride. Liquid 
culture media included 0.02% Tween 80 (T80) to prevent clumping 
of BCG cells. BCG colonies were grown at 37~ on Middlebrook 
7H10 agar media (Difco Laboratories) upplemented with 10% 
volume of AD enrichment. For transformation, BCG cultures were 
grown to densities of "~107 CFU/ml, sedimented at4,000 g, and 
washed twice by resuspension a d centrifugation (4,000g) in 10% 
glycerol at 4~ and finally resuspended in 5% of the original cul- 
ture volume of cold 10% glycerol. 200 #1 of the cold BCG suspen- 
sion was mixed with plasmid DNA (50-500 ng) in a prechilled 
0.2-cm electroporation cuvette and transformed using a gene pulser 
electroporator at2.5 kV, 25/~f, and 1,000 1] (Bio-Rad Laborato- 
ries, Richmond, CA). After electroporation, 50/~1 of 5 x Dubos 
media was added to the BCG-DNA suspension and this mixture 
was incubated at 37~ for 1 h before plating on Middlebrook 7H10 
plates supplemented with AD enrichment and kanamycin (15 
/~g/ml). 
Analysis of OspA Expression i  rBCG. BCG transformants were 
grown to mid-logarithmic phase in Dubos liquid media containing 
kanamycin (15/zg/ml), sedimented at4,000 g, and prepared for 
Western blot analysis by washing in a PBS + 0.05% TSO 20-fold 
concentration by centrifugation and sonication in radioim- 
munoprecipitation assay (RIPA) buffer (1% NP-40, 0.5% deoxy- 
cholate, 0.1% SDS, 50 mM Tris (pH 8.0). Culture lysates approxi- 
mately equivalent to 5 x 106 bacteria were analyzed by SDS-PAGE 
and Western blot with the OspA-specific mAb H5332 (18). Expres- 
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sion of OspA by rBCG was compared to a B. burgdorferi lysate de- 
rived from strain B31 and to purified OspA lipoprotein, kindly 
provided by Dr. L. Erdile (Connaught Laboratories Inc., Swift- 
water, PA). Protein bands reacting with H5332 were visualized 
after incubation with a secondary antibody (goat anti-mouse IgG 
conjugated to horseradish peroxidase) using the enhanced chemi- 
luminescent detection (ECL) system (Amersham Corp., Arlington 
Heights, IL) according to manufacturers specifications. 
Localization of OspA Fusion Proteins in Recombinant BCG by Triton 
X-114 Phase Partitioning. rBCG cells were sedimented from cul- 
tures, suspended inPBS, and cell suspensions were adjusted to equiva- 
lent densities. Cells were disrupted by sonication and membranes 
were solubilized at 4~ by the addition of Triton X-114 (TX-114) 
to 2% (vol/vol). Insoluble material (cell wall-enriched fraction) 
was sedimented by centrifugation at 100,000 g and the supema- 
rant was subjected to detergent phase partitioning (32). After briefly 
warming (37~ the TX-114 solutions, separation of aqueous and 
detergent phases was achieved by a short centtifugation. These two 
phases were back-extracted three times (33), and proteins in repre- 
sentative samples were precipitated by the addition of nine volumes 
of acetone. A portion of each culture supernatant was concentrated 
by ultrafiltration (Centricon 30; Amicon Corp., Danvers, MA). 
Samples representing fivefold concentrated culture volume quiva- 
lents were subjected to SDS-PAGE, transferred to nitrocellulose, 
and blotted with anti-OspA mAb H5332. Endogenous Hsp60, BCG 
o~ antigen (ccAg), and Mtb19 BCG homologous antigens were de- 
tected by Western blot with mAbs IT13, HYT27, and HYT6, 
respectively (kindly supplied by T. Shinnick, Centers for Disease 
Control, Atlanta, GA; and J. Ivanyi, Medical Research Council, 
Hammersmith Hospital, London, UK), as part of the United Na- 
tions Development Program/World Bank/World Health Organi- 
zation Special Programme for Research and Training in Tropical 
diseases. 
Surface Labeling and Flow Cytoraetry of rBCG Expressing OspA. 
Approximately 2 x 109 rBCG grown in Dubos-AD were har- 
vested by centrifugation. The pelleted rBCG were washed with 
10 ml of PBS-T80 (pH 7.4), resuspended in 5 ml PBS-T80, then 
fixed with an equal volume of 4% paraformaldehyde in PBS-T80 
for 10 rain at 4~ Fixed rBCG were pelleted and washed twice 
with 5 ml PBS-T80, then resuspended in a 1-ml volume of PBS- 
T80 for treatment with ot-OspA polyclonal sera. The anti-OspA 
polyclonal serum was generated by hyperimmunization of rabbits 
with purified OspA lipoprotein in IFA. Possible background reac- 
tivity was removed by exhaustive preadsorption with BCG lysate 
immobilized on nitrocellulose membranes. This preadsorbed anti- 
OspA polyclonal sera was added to the fixed rBCG cell suspension 
at a final dilution of 1:200 and incubated for 30 min at room tem- 
perature and 30 rain on ice. The rBCG were pelleted by centtifu- 
gation, washed twice with 0.5 ml PBS-T80, and resuspended in 
1 ml PBS-T80. Goat anti-rabbit FITC-conjugated secondary anti- 
body (GIBCO BRL, Gaithersburg, MD) was added to a final dilu- 
tion of 1:50 and incubated for 30 min on ice. The rBCG-antibody 
complex was pelleted by centrifugation, washed twice with I ml 
PBS-T80, and resuspended in 2 ml PBS-T80. Labeled rBCG were 
mildly sonicated to disperse clumped cells and dilutions were ana- 
e @ lyzed by flow cytomtry on a FACScan (Becton Dickinson & Co., 
Mountain View, CA). 
rBCG Preparation and Immunization. rBCG cultures were grown 
to ODs of "~1.2 A~ U (m2 x 10 s CFU/ml), concentrated 20- 
fold by sedimentation at 4,000g, and resuspended in 15% glycerol. 
1-ml vials of the rBCG glycerol suspension were gradually frozen 
at a rate of - l~ from 4 to -40~ The frozen rBCG were 
stored at -70~ until use. CFU were assayed by plating mildly 
sonicated ilutions of a thawed material on Middhbrook 7H10 plates 
+ kanamycin as described above. 
Female 4-6-wk-old BALB/c and C3H/HeJ inbred mice (The 
Jackson Laboratory, Bar Harbor, ME) and outbred Swiss Webster 
mice (Charles River Labs., Wilmington, MA) were immunized 
(priming and boosting) by the intraperitoneal route with 106 
rBCG CFU in 100/~1 of PBS-T80. 
Iramunogenicity of rBCG-oslx4 Constructs. Sera were collected 
from the tail veins of immunized mice at 4-wk intervals and pooled 
for each group to monitor antibody responses by ELISAs with 
R burgdo!feri (strain B31) spirochetes. ELISA plates (Immulon 1) 
were coated with 50 #1 of whole Borrelia resuspended in 0.1 M 
carbonate buffer (pH 9.6) at 10 #g/ml protein or with 100 #1 of 
recombinant 0.1 ~g/ml OspA in the same carbonate buffer and 
incubated for 2-4 h at room temperature or overnight at 4~ The 
antigen solution was removed and plates were incubated with 
blocking solution (0.5% BSA and 0.5% nonfat dry milk) in PBS 
with 0.1% Tween-20 (PBS-T20) for I h at room temperature. Two- 
fold serial dilutions of serum starting at 1:200 were made in blocking 
solution and 50 #1 of each dilution was added to duplicate wells 
of the antigen-coated plate. After an incubation at room tempera- 
ture for 1 h, the coated plates were washed with PBS-T20 and 
incubated with 50 #1 of a 1:1,000 PBS-T20 dilution of peroxidase- 
conjugated goat anti-mouse IgG (Kirkegaard & Perry Laborato- 
ries, Inc., Gaithersburg, MD) secondary antibody for 1 h. Color 
was developed with 2,2'-azino-di[3-ethyl-benzthiazoline su fonate 
(6)] substrate r agent (Kirkegaard & Perry Laboratories, Inc.) and 
measured by absorbance at405 nm on an ELISA reader (Dynatech). 
Endpoint iters were defined as the highest dilution at which the 
A40s values were twice the values for preimmune sera diluted 1:200 
in blocking solution. 
Western immunoblot analysis was performed with lysates of 
whole R burgdorferi. After separation by SDS-PAGE and transfer 
to nitrocellulose, individual hnes were incubated for 1 h with pooled 
serum diluted 1:500 in PBS-T20, washed with PBS-T20, reacted 
with horseradish peroxidase-conjugated goatanti-mouse secondary 
antibody for 30 rain, and developed with the ECL chemilumines- 
cent substrate according to manufacturer's in tructions (Amersham 
Corp.). 
In Vitro Growth Inhibition Assay. In vitro growth inhibition an- 
tibody titers against he B31 strain of/~ burgdorferi were determined 
as described elsewhere (34) for pooled sera from rBCG-immunized 
mice in two independent experiments. Wells of a 96-we11, flat- 
bottomed microtiter plate were seeded with 2 x 106 spirochetes 
in 0.1 ml of BSK-II media derived from a late log-phase culture 
of a high-passage-number isohte ofR burgdotferi B31 (35210; Amer- 
ican Type Culture Collection) grown in the same medium. Before 
addition to wells mouse serum was heat inactivated (growth inhi- 
bition in this assay is complement independent) and filtered through 
a 0.22-#m filter to sterilize the serum. Twofold serial serum dilu- 
tions starting at 1:8 were added to duplicate culture wells in the 
96-well plates, and the plates were sealed and incubated at 34~ 
for 72 h in a 1% CO2 atmosphere. Bacterial growth in each well 
was monitored by color changes in the phenol red indicator dye 
with a 580 ELISA reader at 490 nm (Dynatech Labs. Inc., Chan- 
tilly, VA). Spirochete growth was also confirmed by phase contrast 
microscopy in control wells. As a control for specificity of serum 
growth inhibition R hermsii strain HSI (35209; American Type Cul- 
ture Collection) was used in the same experiments. 
lg burgdorferi Challenge of Mice Immunized with rBCG-OspA Vac- 
cines. Challenge doses were derived by expansion of a single colony 
of the low-passage R burgdo!feri Sh.2 strain (35) and were ad- 
ministered 5 wk after the rBCG booster immunization. Immunized 
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and control mice were challenged intraperitoneally with 106 
spirochetes in experiment 1. In experiment 2, mice were inocu- 
lated intradermally at the base of the tail with 104 spirochetes. 
This represented '~100 IDs0 units of the B. burgdorferi Sh.2 strain. 
Mice were killed 14 d after challenge, and plasma and bladder, heart, 
and joint tissues were harvested, minced, and cultured in BSK-II 
media s described previously (31). Cultures were monitored through 
day 14 by phase contrast microscopy for the presence ofspirochetes. 
The presence of one or more spirochetes per 20 high-power fields 
in any one of the blood or tissue cultures was scored as a positive 
infection. 
Results 
Expression of Membrane-associated OspA Lipoprotein on Recom- 
binant BCG. Initial studies in this laboratory with an rBCG 
vaccine expressing OspA at high levels in the cytoplasm of 
rBCG resulted in modest anti-OspA humoral responses (36). 
We therefore initiated strategies to express OspA as an ex- 
ported membrane-associated lipoprotein wi h the aim of en- 
hancing OspA immunogenicity in rBCG. Mice and humans 
immunized with BCG or infected with Mycobacterium tuber- 
culosis often exhibit higher titered antibody responses to a 
19-kD antigen (Mtb19) than to the numerous other antigens 
of these mycobacteria (37, 38). DNA sequence analysis of 
the gene encoding the immunogenic Mtb19 antigen of 
M. tuberculosis indicated that the hydrophobic NH2-terminal 
region was a lipoprotein signal peptide (39). Subsequent bio- 
chemical analysis confirmed that the Mtb19 protein was lipid 
acylated by M. tuberculosis, presumably during the export pro- 
cess (40). Accordingly, weconstructed expression vectors using 
the Mtb19 lipoprotein signal peptide in an attempt o direct 
the expression, export, and lipid acylation f heterologous 
antigens, such as OspA, by recombinant BCG. For compar- 
ison, an expression vector was also constructed for expres- 
sion of fusion proteins with the olAg, which is a 32-kD 
secreted protein found in the culture filtrate BCG85 com- 
plex of BCG and other mycobacteria (41-45). The c~Ag homo- 
logue ofM. kansasii has been used previously as a carrier pro- 
tein to secrete an HIV-1 Gag peptide from rBCG, but immune 
responses using this strategy have not been reported (44, 45). 
As a bacterial lipoprotein with promising vaccine f~cacy, 
OspA was chosen as an appropriate antigen to test the utility 
of the rBCG lipoprotein expression vectors (LPE vectors). 
With the aim of comparing immune responses to rBCG ex- 
pressing OspA as a cytoplasmic protein (C-OspA), a secreted 
protein (S-OspA), or as a membrane-associated lipoprotein 
(L-OspA), we cloned an ospA gene segment excluding the 
5' signal peptide region (OspA A1-18) into rBCG expres- 
sion vectors pMV261, pAB26, and p19PS, respectively (Fig. 
1). A complete ospA gene segment including its native signal 
peptide was lso cloned into rBCG expression vector pMV251 
in an attempt to derive expression of a complete and authentic 
OspA lipoprotein in rBCG (Fig. 1). Recombinant gene prod- 
ucts that were reactive with a mAb specific for OspA were 
obtained at the predicted molecular weights for all ospA con- 
structs described above (Fig. 2). Expression levels of the OspA 
protein from the rBCG-pMV261::ospA construct were esti- 
mated to be in excess of 10% total rBCG protein ('~20 
Promotor Secretion Sional Antioen Gene 
pMV261::ospA ~ ~ n ~ o  = = i n n n a t a n n ~ 11 n
(C-OspA) 
pMV251::ospA ~ - - - - ~ - . ~  
(L-OspA) 
p19PS::ospA ~ 
(L19-OspA) 
pAB26::ospA ~~i~~1~L~ 
(S-O~oA) 
hsp60 m BCG "heat shock" gene 
ospA ~ Borrelia burgdorferi lipoprotein gene 
mtb 19 ~ M. tuberculosis lipoprotein gene 
c(-ag ~ secreted mycobacterial protein gene 
Figure 1. BCG/E. coli shuttle xpression vectors used to express o pA. 
ng/106 rBCG), while expression levels for OspA fusions to 
the Mtb19 signal peptide, the c~Ag, or the native OspA signal 
peptide were substantially ower ('~1-5 ng/106 rBCG). Sur- 
prisingly, chimeric OspA lipoproteins and the o~Ag-OspA 
fusion protein were s emingly more reactive in Western blot 
analyses with the OspA-specific H5332 mAb even though 
these gene products were expressed atmuch lower levels than 
the fusion protein expressed by pMV261::ospA (Fig. 2). This 
observation is probably explained by increased avidity of the 
o~Ag-OspA fusion protein and lipid acylated OspA lipopro- 
tein for the nitrocellulose membrane, as described in a previous 
study (30), since nonlipid acylated OspA has been shown to 
be antigenically equivalent to OspA lipoprotein (31). 
Figure 2. Expression f ospA in rBCG. Plasmids constructed in E. coli 
as described in Fig. I were transformed into BCG substrain Pasteur 1173A2 
by electroporation. Transformants were grown and '~5 x 106 rBCG bac- 
teria were harvested and analyzed by SDS-PAGE (top) and Western blot 
with OspA-specific mAb H5332 (bottom) for comparison to a/~ burgdorferi 
lysate, and purified OspA lipoprotein. 
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Figure 3. Localization of OspA fusion proteins in recombinant BCG 
by TX-114 phase partitioning, rBCG lysates were ffactionated by centrifuga- 
tion and TX-114 phase partitioning as described in Methods. Samples 
representing fivefold concentrated culture volume equivalents were sub- 
jected to SDS-PAGE, electroblotted o nitrocellulose, and reacted with anti- 
OspA mAb H5332 (left). Identically processed fractions from nonrecom- 
binant BCG were blotted with appropriate mAbs specific for the BCG 
orM. tuberru/a~ hsp60 (IT13), o~-Ag (HYT27), or Mtb19 antigens (HYT6) 
to determine the cellular location of the endogenous fusion partners. Lane 
W, whole cell sonicate; lane I, TX-114-insoluble material (cell wall en- 
riched); lane/1, aqueous phase (cytosol enriched); lane D, detergent phase 
(membrane/lipoprotein enriched); lane M, fivefold concentrated culture 
medium (secreted). Positions of chimeric OspA protein hands are indi- 
cated by arrows at 31 kD. Positions of the endogenous BCG proteins used 
as fusion partners are indicated on the right with the molecular masses 
(in kD). 
To determine if expression of ospA genes from the lipo- 
protein expression vectors actually resulted in export and lipid 
acylation of recombinant OspA, exponentially growing cul- 
tures of the rBCG-OspA recombinants and nonrecombinant 
BCG were subjected to cell fractionation a d TX-114 deter- 
gent phase partitioning analysis to enrich for membrane- 
associated lipoproteins (32, 33). The OspA gene product en- 
coded by pMV261::ospA (C-OspA) was found exclusively in
the aqueous cytosolic fraction and correlated with the restricted 
cytoplasmic location of the BCG Hsp60 (Fig. 3). The o.Ag-ospA 
gene product (S-OspA) expressed by plasmid pAB26::ospA 
as well as the endogenous BCG c~Ag were found in the in- 
soluble cell wall-enriched fraction, aqueous cytosolic frac- 
tion, and the extraceUular media fraction, but not in the 
detergent-soluble membrane-enriched fraction. The presence 
of the otAg-OspA fusion protein or ccAg in the rBCG cul- 
ture media was not due to rBCG autolysis inasmuch as sp60, 
which we determined tobe exclusively cytosolic in exponen- 
tially growing cultures, was not found in the culture media. 
Compared with the native BCG nAg, a smaller fraction f 
the total S-OspA fusion protein pool was secreted into the 
media, while a larger portion was found in the cell wall-en- 
riched insoluble fraction. This suggested that some of the 
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exported ocAg fusion protein associated with the cell wall, 
although the possibility that some of the c~Ag-OspA is ex- 
pressed as an insoluble cytoplasmic inclusion can not be ex- 
cluded by these data. Substitution of the Mtb19 signal pep- 
tide for the OspA signal peptide resulted in expression of 
a chimeric OspA (L19-OspA) that was almost exclusively o- 
cated in the detergent-soluble fraction, which is highly en- 
riched for lipophilic proteins. This finding correlated with 
the location of the endogenous membrane-associated Mtb19 
lipoprotein BCG homologue and indicated that fusion of the 
Mtb19 signal peptide to OspA did indeed direct efficient ex- 
port and posttranslational modification of the chimeric L19- 
OspA protein to the membrane of rBCG. This result was 
in contrast to the predominantly c tosolic location for the 
gene product encoded by pMV251::ospA (L-OspA), where 
a very minimal amount of OspA was found in the detergent- 
soluble lipophilic fraction. This result was possibly indica- 
tive of inefficient or incomplete processing of the foreign 
Borrel/a signal peptide bythe my~obacterial lipoprotein-specific 
signal peptidase II. 
The rBCC-OspA bacilli were also analyzed byflow cytom- 
etry to confirm predictions of the cellular localization f the 
recombinant OspA gene products (Fig. 4). rBCG expressing 
L19-OspA, L-OspA, and S-OspA, from plasmids p19PS::osFA, 
pMV251::ospA, and pAB26::ospA, respectively, all demon- 
strated increased surface fluorescence with anti-OspA sera when 
compared with nonrecombinant BCG or rBCG expressing 
C-OspA from plasmid pMV261::ospA. Although discernibly 
less than that of rBCG expressing L19-OspA, the surface 
fluorescence exhibited by rBCG with plasmid pMV251::ospA 
was somewhat surprising in light of the finding that the 
majority of this OspA protein was cytosolic. Nevertheless, 
this finding was in general agreement with the TX-114 ffac- 
tionation analysis, which indicated that a small amount of 
lipophilic L-OspA was associated with the BCG membrane 
as a lipophilic protein. The rBCG expressing the S-OspA from 
vector pAB26::ospA also exhibited surface fluorescence, thus 
confirming the finding that the oLAg-OspA fusion protein 
found in the TX-114-insoluble fraction was cell wall associated 
and not derived primarily from insoluble cytoplasmic inclu- 
sion bodies. Further confirmation of OspA surface localiza- 
tion by fusion to the Mtb19 lipoprotein signal peptide or c~Ag 
in rBCG was obtained by immunoelectron microscopy of 
rBCG thin sections (data not shown, S. Hanson et al., manu- 
script in preparation). These data, taken together with the 
fractionation and TX-114 phase partitioning analysis, confirm 
that it is possible to export OspA to the exterior of rBCG 
as a chimeric membrane-associated lipoprotein by fusion to 
the Mtb19 lipoprotein signal or s a secreted and cell wall-as- 
sociated protein by fusion to the c~Ag. 
Enhanced Humoral Response to rBCG Membrane-associated 
OspA. A survey of 24 inbred and outbred mouse strains was 
performed to determine r lative humoral responsiveness to 
recombinant OspA expressed in the cytoplasm ofrBCG and 
to determine whether the mouse BCG allele, which confers 
resistance orsensitivity to in vivo growth of BCG and other 
intracellular pathogens, had any impact on responsiveness to 
rBCG-expressed OspA (46). OspA-specific antibody responses 
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Figure 4. Surface labeling and 
flow cytorrletry of rBCG expressing 
OspA. rBCG containing the desig- 
nated plasmids and expressing the 
designated chimeric OspA gene 
products (shaded histograms) are com- 
pared to nonrecombinant BCG 
(open histograms). 
resulting from immunization with rBCG pMV261::ospA ex- 
pressing C-OspA did not correlate with the mouse BCG al- 
lele, as responding mouse strains carrying either BCG-s (sen- 
sitive) and BCG-r (resistant) alleles were observed (46). 
C3H/He, BALB/c, and outbred Swiss Webster mice responded 
to rBCG-pMV261::ospA immunization with high (not re- 
quiring boosting), intermediate (requiring boosting), and low 
(barely detectable after boosting) anti-OspA responses, respec- 
tively. In addition to their variable responses to OspA, these 
mouse strains differ with respect to their resistance to BCG 
growth; BALB/c mice carry the BCG-s (sensitive) allele and 
both C3H and outbred Swiss Webster mice are BCG-r (resis- 
tant). Thus, these three mouse strains provided a manage- 
able representative sampling of mouse phenotypes for com- 
parison of rBCG vaccines expressing OspA as a cytoplasmic 
protein, a membrane-associated lipoprotein, or as a cell wall-as- 
sociated and secreted protein. C3H/HeJ, BALB/c, and the 
outbred Swiss Webster mice were immunized intraperitoneaUy 
with 106 CFU of rBCG-OspA and pooled sera were ana- 
lyzed by ELISA to whole Borrelia at 4, 8, 12, and 16 wk after 
a single immunization. All mice were boosted at 17 wk with 
the same rBCG vaccine used in the initial immunization and 
sera were analyzed for reactivity to OspA 2 wk postboost. 
All three mouse strains immunized with rBCG vaccines ex- 
pressing OspA as lipoproteins (L-OspA and L19-OspA) ex- 
hibited strong OspA-specific antibody responses within 4-8 
wk after a single rBCG-OspA immunization, as measured 
by ELISA to whole Borrelia (Fig. 5). Similar responses to rBCG 
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Figure 5. Comparison of im- 
munogenicity of rBCG-ospA con- 
structs (cytoplasmic, secreted, and 
lipid acylated). Mouse strains were 
immunized by the intraperitoneal 
route with 10 6 CFU of rBCG and 
boosted at 17 wk with the identical 
dose. Sera were collected at the in- 
dicated times, pooled, and analyzed 
by ELISA with whole B~ burgdorferi 
(strain B31). 
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Table 1. Anti-OspA Endpoint Titers (Exp. I) 
rBCG vector* 
immunogen 
Mean anti-OspA endpoint iter* 
mouse serum (2 wk postboost) 
BALB C3H Swiss 
pMV261::ospA 400 +_0 400 +_ 0 400 + 0 
(C-OspA) 
pMV251::ospA 289,631 _+ 58,341 243,550 _+ 42,415 204,800 _+ 0 
(L-OspA) 
p19PS::ospA 243,550 _+ 42,415 819,200 _+ 0 43,054 _+ 7,498 
(L19-OspA) 
pAB26::ospA 2,691 _+ 469 12,800 _+ 0 951 _+ 166 
(S-OspA) 
BCG controls 400 _+ 0 200 _+ 0 400 _+ 0 
* Vector used to express OspA gene in rBCG vaccine. 
ELISA to purified OspA lipoprotein. 
S Nonrecombinant BCG (Pasteur substrain). 
C-OspA were not seen until after boosting. Particularly 
striking were the anti-OspA responses elicited by a single 
dose of either of the rBCG-L-OspA vaccines in the low re- 
sponder outbred Swiss Webster mice. This mouse strain im- 
munized with rBCG expressing OspA as a cytoplasmic or 
secreted protein did not mount anti-OspA responses even after 
boosting. Peak anti-OspA antibody titers >1:10 s in BALB/c 
and C3H mice and 1:104 in Swiss mice were elicited by 
boosting with rBCG-L-OspA constructs. These responses 
were 100-1,000-fold higher than the responses induced with 
rBCG constructs expressing as a cytoplasmic protein or secreted 
surface-associated OspA-ctAg fusion protein. The specificity 
of antibodies (pooled sera) to OspA generated by immuniza- 
tion with rBCG-OspA vaccines was confirmed by ELISA with 
purified OspA lipoprotein (Table 1) and Western blot anal- 
ysis with R burgdorferi lysates (Fig. 6). Analysis of ndividual 
mouse anti-OspA titers revealed that all mice immunized with 
BCG-L-OspA vaccines responded comparably, while signi- 
ficant individual mouse-mouse variation was observed in 
animals immunized with rBCG vaccines expressing C-OspA 
or S-OspA (data not shown). 
Protection against li burgdo~'eri Infection with an rBCG-based 
Vaccine. The OspA antigen ofR burgdorferi has been shown 
to be protective inboth immunocompetent a dimmunode- 
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Figure 6. Western blot reac- 
tivity of antibodies elicited by
rBCG-OspA vaccines. A R burgdor. 
fen' lysate (strain B31) was reacted 
with pooled immune sera collected 
2 wk after a single booster immu- 
nization from rBCG-immunized 
BALB/C, C3H/HeJ, or Swiss Web- 
ster mice. Pooled immune sera was 
derived from mice immunized with 
rBCG expressing OspA from 
vectors pMV261::ospA (C-OspA, 
lanes 1), pAB26::ospA (S-OspA, 
lanes 2), plgPS::ospA (L19-OspA, 
lanes 3), pMV251::ospA (bOspA, 
hnes 4), from mice immunized with
control nonrecombinant rBCG 
(BCG Pasteur, lanes 5), or from 
mice bled before immunization 
(pt~immune s n, lane 6). Identical 
R burgdorfer/lysates w re also reacted 
with OspA-specific mAb H5332 
(lane M) and anti-OspA hyperim- 
mune rabbit sera (lane P). 
Table 2. In Vitro Growth Inhibition Titers and In Vivo Protection against B. burgdo!feri Challenge (Exp. I) 
In vitro growth 
inhibition titer* of 
mouse serum 
In vivo protection: no. mice with culturable 
borrelia in tissues or blood/total no. mice* 
Bladder culture Heart culture 
rBCG vector s 
immunogen BALB C3H BALB C3H BALB C3H 
pMV261: :ospA <8 32 5/5 3/4 1/5 0/5 
(C-Osp^) 
pMV251::ospA 4,096 1,024 0/5 0/5 0/5 0/5 
(L-OspA) 
p19PS: ospA 1,024 2,048 0/5 3/5 0/5 0/5 
(L19-OspA) 
pAB261::ospA ND 256 4/5 3/5 1/5 1/5 
(S-OspA) 
BCG control II <8 <8 4/4 5/5 3/4 3/5 
B. burgdorferi challenge used 106 CFU of low-passage SH.2 strain (31, 35). 
* Number of mice in each group testing positive for borrelia infection (low-passage Sh.2 strain) by culture of tissues 14 d after challenge as a fraction 
of the total number of mice per group (31). 
* Reciprocal of the highest dilution of mouse serum at which borrelia growth is inhibited in culture (34). 
S Vector used to express OspA gene in rBCG vaccine. 
Ir Nonrecombinant BCG (Pasteur substrain). 
ficient mouse models for Lyme borreliosis, and this protec- 
tion has been shown to be antibody mediated (27-29). Im- 
mune sera collected 2 wk after a single booster immuniza- 
tion of C3H and BALB/c mice immunized with the different 
rBCG-OspA vaccines were analyzed for their ability to in- 
hibit growth of the cuhure-adapted B31 laboratory strain of 
B~ burgdorferi in vitro (34). Antisera derived from immuniza- 
tions with both rBCG-L-OspA vaccines (rBCG-p19PS::ospA, 
rBCG-pMV251::ospA) exhibited high-titered/~ burgdorferi 
growth-inhibiting activity, while sera derived from mice 
immunized with the rBCG-C-OspA vaccine (rBCG- 
pMV261::ospA) or nonrecombinant BCG showed low or un- 
detectable growth-inhibiting titers (Table 2). In identical assays, 
immune sera from rBCG-OspA-immunized mice failed to 
inhibit the growth of/g hermsii, which does not express OspA 
(data not shown). This demonstrated that growth inhibition 
was OspA specific and not due to a nonspecific mode of ac- 
tion against borrelias. 
Based on these results, C3H and BALB/c mice were chal- 
lenged intraperitoneaUy with 106 borrelia spirochetes derived 
from an infectious clone of the low-passage Sh.2 strain of 
13, burgdorferi (35) of the same OspA serogroup as B31 (47). 
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Figure 7. Immunogenicity of 
rBCG bospA constructs. The indi- 
cated mouse strains were im- 
munized by the intraperitoneal route 
with 106 CFU of the indicated 
rBCG and boosted at 17 wk with 
an identical dose. Sera were collected 
at the indicated times from each 
,~-~ o~"  ~ o ~-~ ~v ''~ o ~-~" group (five mice), pooled, and ana- 
l I I I I _ _ l  lyzed by ELISA with whole/~ burg. 
pMVZ61 ::gp41 pMV2Sl ::ospA pl 9PS:ospA d~ct1' (.4) and in the in vitro growth 
(neg, control) (L-OspA) (L19-OspA) inh ib i t ion  assay  (B) (34). 
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The ability of rBCG-OspA-immunized mice to inhibit 
lg burgdogCeri g owth in vivo was assayed by culture of bladder 
and heart issues taken from mice 2 wk after challenge, the 
normal peak of spirochetemia in a borrelia-infected mouse. 
All mice immunized with an irrelevant BCG control were 
found to be infected, as determined bypositive borrelia cul- 
ture from bladder tissue. Heart cultures appeared tobe a less- 
sensitive indication of infection in these control mice. Three 
of four groups of mice immunized with rBCG-OspA lipo- 
protein vaccines were completely protected from intraperitoneal 
challenge with 106 spirochetes, asdetermined bybladder cul- 
ture of borrelia (Table 2). Evidence of borrelia breakthrough 
was observed with this high-challenge dose in one group of 
C3H mice immunized with the rBCG-p19PS vaccine despite 
substantial neutralizing antibody titers. However, this rBCG 
L-OspA vaccine completely protected BALB/c mice. In con- 
trast, immunization with rBCG vaccines expressing OspA 
as a cytoplasmic protein, or as a secreted/cell wall-associated 
protein, resulted in incomplete protection against challenge. 
Some reduction i  culturable borrelia from heart issue was 
observed, but no significant differences were found in the 
culture of the bladder tissues compared with control BCG- 
immunized mice (Table 2). 
It has been shown that the intradermal route of borrelia 
challenge ismore efficient for establishing infection in mice 
and is presumably more relevant to an infection delivered by 
a tick bite (48). Therefore, in a second experiment we deter- 
mined whether the rBCG-L-OspA vaccines eliciting the 
highest antibody titers and protective responses against in- 
traperitoneal borrelia challenge (rBCG-pMV251::ospA and 
rBCG-plgPS::ospA) could similarly protect mice against in- 
traderrnal challenge. As in the first experiment, C3H, BALB/c, 
and Swiss mice were immunized intraperitoneaUy with 106 
CFU of each rBCG vaccine, and boosted at 17 wk. All three 
strains of mice immunized with rBCG-L-OspA vaccines again 
exhibited high OspA-specific antibody titers before and after 
boost, while mice immunized and boosted with an irrele- 
vant BCG control did not (Fig. 7 A). Immune sera collected 
from C3H and BALB/c mice 8 wk after the primary immu- 
nization with rBCG-L-OspA vaccines exhibited substantial 
growth-inhibiting antibody titers (1:500-1,000), while sera 
from all three mouse strains collected 2 wk postboost ex- 
hibited higher growth-inhibiting antibody titers (Fig. 7 B). 
All immunization groups were challenged intradermally 4 
wk postboost with 104 borrelia, and plasma, bladder tissue, 
and tibiotarsal joints were cultured for detection of borrelia 
infection 14 d postchallenge. Both rBCG-L-OspA vaccines 
completely protected allthree mouse strains against intradermal 
challenge; spirochetes could not be cultured from any of the 
tissues or plasma tested (Table 3). In contrast, all mice im- 
munized with a control irrelevant recombinant BCG were 
shown to be infected, as indicated by the positive culture of 
t?, burgdolferi spirochetes from either plasma, bladder, or joint 
tissues. The 104 borrelia challenge dose used in this in- 
tradermal challenge xperiment is roughly estimated to be 
comparable to an infection from 5-50 infected flat nymphal 
stage ticks (Ixodes dammini) (49). 
Discussion 
Significant progress has been made toward the identification 
of protective antigens for a wide variety of diseases but basic 
difficulties central to practical vaccine development still exist. 
Among the most formidable obstacles i the cost-effective 
production of immunogenic vaccine components insuffident 
quantities for wide use and the ddive,'y of these components 
Table 3. Protection against Intradermal Challenge with B. burgdorferi (Exp. 2) 
In vivo protection:* no. mice with culturable borrelia in tissues or blood/total no. mice 
Bladder culture Blood culture Joint culture Total culture positive* 
rBCG vector s 
immunogen BALB C3H Swiss BALB C3H Swiss BALB C3H Swiss BALB C3H Swiss 
pMV251::ospA 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
(L-OspA) 
p19PS::ospA 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
(L19-OspA) 
pMV261::gp411r 4/4 4/5 2/5 4/4 4/5 4/4 3/4 4/5 2/4 4/4 5/5 4/4 
(rBCG control) 
100 LDs0 (104 spirochetes) of low-passage Sh.2 strain (31, 35). 
* Number of mice in each group testing positive for borrelia infection by culture of tissues 14 d after challenge as a fraction of the total number 
of mice per group (31). 
* Number of mice culture positive for any single tissue or blood culture. 
S Vector used to express OspA gene in rBCG vaccine. 
II rBCG expressing HIV-1 gp41 in expression vector pMV261 (1). 
205 Stover et al. 
in a safe and immunogenic form. One approach taken to over- 
come vaccine production and delivery problems i the devel- 
opment of live attenuated vaccines that replicate and express 
protective antigens in vivo. With the development of recom- 
binant DNA methodology has come approaches to modify 
live attenuated vaccines, (e.g., pox viruses and Salmonella) to 
produce heterologous antigens protective against a variety 
of diseases. As a widely used human vaccine against tubercu- 
losis, the live attenuated BCG vaccine also offers consider- 
able advantages for development as a multivalent vaccine ve- 
hicle for other human pathogens (4). With the recent 
development of genetic vector systems for the slow-growing 
mycobacteria, it is now possible to evaluate the potential for 
recombinant BCG as a multivalent live carrier for inducing 
protective immunity to heterologous antigens (1-5). 
Inasmuch as BCG is rapidly ingested by macrophages and 
grows within the macrophage phagolysosome, rBCG is usu- 
ally thought of as a vaccine vehicle for eliciting stronger cel- 
lular responses than humoral responses. Initial studies with 
model rBCG vaccines expressing E. coli fl-galactosidase indi- 
cated that substantial cellular and humoral responses to target 
antigens delivered as rBCG cytoplasmic proteins were pos- 
sible (1). Subsequent follow-up studies with a number of target 
antigens expressed in the cytoplasm of rBCG have indicated, 
however, that primary target antigen-specific antibody re- 
sponses in mice are generally more difficult o obtain or are 
highly variable and strain specific. To improve the potential 
of recombinant BCG vaccines to elicit protective humoral 
responses to target antigens, we have developed expression 
vectors using signal sequences derived from mycobacterial li- 
poproteins todirect he export of recombinant target antigens 
to the membrane of the BCG carrier as immunogenic chi- 
meric lipoproteins. This strategy was based on the reasoning 
that bacterial lipoproteins are membrane associated, some- 
times located at the surface of the bacterium, and are often 
among the most immunogenic antigens recognized by the 
infected host's humoral immune response (15-22). In the case 
of M. tuberculosis, atleast two lipoproteins, the 19- and 38- 
kD (Mtb19 and Mtb38) antigens, are among the most im- 
munogenic of antigens recognized by infected humans (37, 
38). While the immunogenic nature of some lipoproteins 
may be due in part to their location in the membranes 
of bacteria, evidence ismounting that the inherent immuno- 
genicity of lipoproteins i due in large part to the NH2-ter- 
minal ipid moiety. This has now been directly demonstrated 
for OspA (31, and this study). Furthermore, chemical lipid 
acylation of peptides and proteins can profoundly enhance 
their immunogenicity (12, 13). A definitive xplanation for 
this widely observed augmentation fimmunogenicity is not 
yet available, but as free lipoproteins orlipopeptides, it might 
be possible that the NH2-terminal lipid moieties might as- 
sociate as micelles, which could be more readily taken up by 
APCs. This could then enhance antigen presentation to T 
cells, which could in turn result in improved T help for cyto- 
toxic cellular esponses and B cell humoral responses. While 
this explanation might be tenable for subunit vaccines it does 
not explain why a lipoprotein expressed on rBCG, which 
is readily taken up by APCs, might be more immunogenic 
than the same antigen expressed in the cytoplasm of BCG. 
It is perhaps possible that exterior lipoproteins of rBCG are 
shed and are therefore more rapidly available to antigen pro- 
cessing mechanisms in the macrophage phagolysosome than 
are BCG cytoplasmic proteins. It might also be possible that 
L-OspA expressed on the surface of rBCG can directly prime 
B cells when BCG are extracellular, resulting in a synergistic 
response that normally does not occur to the same antigen 
expressed in the cytoplasm of BCG. Yet other explanations 
might be based on alternative antigen processing pathways 
for lipoproteins or the possibility that some lipoproteins or 
lipopeptides are mitogenic (12, 14). It should be noted, how- 
ever, that enhanced humoral immune responses toBCG an- 
tigens were not observed in mice immunized with rBCG 
L-OspA vaccines (data not shown), arguing against the pos- 
sibility that L-OspA expression i  rBCG is somehow mito- 
genic. The elucidation of the mechanism by which lipid acy- 
lation enhances OspA reactivity requires further study. Such 
studies hould include a comparison of T cell responses to 
OspA and additional antigens expressed cytoplasmically or
extracellularly as lipoproteins or secreted proteins. 
The insoluble nature of lipoproteins makes them gener- 
ally more di~cult o evaluate as candidate vaccines (e.g., OspA; 
30). It is also likely that some lipoproteins require membrane 
association to exhibit authentic conformational epitopes. The 
expression of target lipoprotein antigens in rBCG obviates 
the need to purify the membrane-bound and insoluble lipo- 
proteins, and presents the opportunity to express these an- 
tigens in a more authentic membrane-associated context. In 
addition to the delivery of natural lipoproteins by rBCG, it 
may be possible to enhance the immunogenicity of non- 
lipoprotein antigens by making them chimeric lipoproteins 
fused to mycobacterial signal peptides. While many target 
antigens will be refractory to export and lipid acylation by 
rBCG, additional studies in this laboratory indicate that some 
nonlipoprotein a tigens can also be exported and lipid modified 
with the Mtb19 and Mtb38 lipoprotein (50) signal sequences 
using the same LPE vectors described in this study (e.g., PspA 
of Streptococcus pneurnoniae; Stover et al., manuscript inprep- 
aration). Studies are in progress to determine whether the 
immunogenicity of nonlipoprotein target antigens can be en- 
hanced by rBCG delivery as chimeric membrane-associated 
lipoproteins. In comparison with other approaches involving 
the grafting of epitopes into bacterial cell surface structures, 
the chimeric lipoprotein approach used in this study has sev- 
eral advantages: (a) only minimal sequence information may 
be necessary to direct export of recombinant target antigens; 
(b) the signal peptide directing export is ultimately removed, 
minimizing contextual effects on important antigenic deter- 
minants; and (c) the target antigen is membrane anchored 
by means of an NH2-terminal lipid moiety that may enhance 
immunogenicity (11-14). Since BCG has a single membrane, 
it may also be generally easier to export foreign antigens from 
rBCG than it is in Gram-negative bacterial vector systems 
with inner and outer membranes separated by a periplasmic 
space. 
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By all immunological nd functional criteria measured, 
rBCG vaccines expressing OspA as a lipoprotein were supe- 
rior to rBCG vaccines that express OspA in their cytoplasm 
or as a secreted/surface protein associated, at least in part, 
with the BCG cell wall. rBCG-OspA lipoprotein vaccines 
elicited earlier, higher titered, protective anti-OspA responses 
that were consistent from mouse to mouse. These protective 
humoral responses were also induced in mice that are lower 
responders toOspA. The comparison ofanti-OspA responses 
generated by rBCG expressing L-OspA and L19-OspA with 
the responses generated by rBCG expressing secreted surface- 
expressed S-OspA suggests hat lipid acylation of OspA may 
have a greater impact on the potential to generate humoral 
responses to OspA than surface xpression by BCG. How- 
ever, a strict comparison is not possible with these data as 
it was necessary to fuse OspA to a full-length secreted pro- 
tein (c~Ag) to obtain a secreted/cell wall-associated fusion 
protein. It is of interest hat rBCG expressing potentially 
authentic OspA polypeptide encoded by plasmid pMV251::ospA 
exhibited surface fluorescence and elicited a high-titered and 
protective anti-OspA response even though only a very small 
amount of the protein appears to be authentically processed 
(lipid-modified L-OspA) in comparison with rBCG vaccine 
expressing L19-OspA from plgPS::ospA. This may occur be- 
cause the borrelia OspA signal peptide issufficiently dissimilar 
from that recognized by mycobacterial cylation enzymes, 
so that this lipid modification, a prerequisite for signal pepti- 
dase II-mediated export, occurs very inefficiently. The 
nonacylated OspA might hen be exported by the major signal 
peptidase I-mediated pathway. However, this explanation 
would also require OspA to be anchored to the exterior of 
BCG in the absence of lipid modification (OspA protein was 
never found in rBCG-pMV251::OspA culture supernatants) 
and would also suggest that BCG surface-expressed nonlipid 
acylated OspA is very immunogenic. These xplanations seem 
unlikely in light of the recent evidence that purified free OspA 
lipoprotein isprofoundly more immunogenic than nonlipid 
acylated OspA (31). Rather, it is more likely that the BCG- 
pMV251::OspA vaccine is very effective because only a very 
small amount of L-OspA in the context of rBCG is actually 
necessary to achieve nhanced anti-OspA immune responses. 
This small amount of authentic L-OspA expressed inrBCG- 
pMV251::osivA may be more immunogenic per molecule 
equivalent simply because it is more authentic than the lipid- 
modified chimeric L19-OspA, which carries an additional five 
amino acid residues from the Mtb19 lipoprotein as its NH2 
terminus. It is also of interest that rBCG expressing OspA 
as a membrane-associated lipoprotein are attenuated in their 
ability to replicate and persist in vivo as compared with non- 
recombinant BCG (data not shown). This is in contrast to 
what one would expect for a live vaccine, which elicits en- 
hanced target antigen-specific immune responses. The effect 
of this attenuation  the ability of the rBCG vaccine to elicit 
cell-mediated immunity and to protect against M. tuberculosis 
challenge iscurrently under investigation i the mouse model. 
Although comparisons between immune responses licited 
by OspA lipoprotein subunit vaccines with live rBCG-OspA 
vaccines were not the aim of this study, comparisons with 
a recently published study on a purified L-OspA subunit vac- 
cine (31) suggest advantages for the delivery of OspA lipo- 
protein by rBCG. Comparison of growth inhibition titers 
obtained from both studies is possible as these titers were 
obtained from the same mouse strain sera (BALB/c and C3H) 
by identical assays in the same laboratory (Sadziene, A., un- 
published ata). Primary immunization a d boosting of C3H 
mice and BALB/c mice with the highest doses tested (10 and 
2.5/~g, respectively) resulted in maximum growth inhibi- 
tion titers of 1:1,024 and 1:512 in the previous tudy on the 
L-OspA subunit vaccine (31). In experiment 1 of the present 
study, immunization a d boosting of the same mouse strains 
with either BCG L-OspA vaccine resulted in borrelia growth- 
inhibiting titers ranging from 1:1,024 to 1:4,096. Higher 
growth-inhibiting titers (1:8,924-32,768) were obtained in 
C3H and BALB/c mice in experiment 2. Moreover, immu- 
nization of three different mouse strains with a single dose 
of rBCG L-OspA and L19-OspA vaccines resulted in sub- 
stantial anti-OspA titers ranging from 1:103 in the outbred 
Swiss Webster mouse to 1:104 in the inbred C3H and 
BALB/c mice. These primary responses, which lasted in >16 
wk, resulted from immunization with a rBCG inocula of 
104 CFU that initially contained only 1-5 ng of L-OspA. 
In the previous tudy, immunization with 10 #g of purified 
L-OspA (200-1,000-fold more L-OspA than delivered in the 
initial rBCG L-OspA inoculum) elicited very weak but de- 
tectable primary responses inthe more OspA-responsive C3H 
mice, while primary responses in the less OspA-responsive 
BALB/c mice were not reported (31). These observations sug- 
gest the enhancement of OspA immunogenicity b  delivery 
as a membrane-associated lipoprotein on the live rBCG vac- 
cine vehicle. It is possible that this is the result of adjuvant 
effects provided by the BCG cell wall, and/or a persistent 
"slow release" of OspA antigen by the live rBCG vaccine, 
which may continually restimulate 'he immune response as 
the organism persists or grows in the host. 
These studies have provided the first demonstration f pro- 
tection elicited by a recombinant BCG vaccine and the devel- 
opment of a promising candidate vaccine for the im- 
munoprophylaxis of Lyme disease. Delivery of OspA as a 
lipoprotein i  the live replicating rBCG vector not only ob- 
viates the need to purify and formulate sufficient quantities 
of an OspA subunit vaccine, but rBCG delivery may also 
elicit more uniform responses invaccinees of a heterogeneous 
genetic background. Further studies are necessary to deter- 
mine whether the immunogenicity of other lipoprotein and 
nonlipoprotein target antigens can be enhanced by delivery 
as chimeric membrane-associated lipoproteins on rBCG. We 
are also investigating whether this approach will also enhance 
cellular immune responses to target antigens delivered by 
rBCG. Such studies could illuminate the mechanism bywhich 
lipid modification or membrane-associated expression can aug- 
ment antigen immunogenicity. 
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